Piper Sandler Maintains Overweight on Abivax, Raises Price Target to $175

Benzinga · 07/09 15:59
Piper Sandler analyst Allison Bratzel maintains Abivax (NASDAQ:ABVX) with a Overweight and raises the price target from $165 to $175.